Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy

Published:2022-09-06 Issue:18 Volume:65 Page:12002-12013
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Fetse John¹,Zhao Zhen¹,Liu Hao¹,Mamani Umar-Farouk¹,Mustafa Bahaa¹^ORCID,Adhikary Pratik¹^ORCID,Ibrahim Mohammed¹^ORCID,Liu Yanli¹,Patel Pratikkumar¹,Nakhjiri Maryam¹,Alahmari Mohammed¹,Li Guangfu²,Cheng Kun¹^ORCID

Affiliation:

1. Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, Missouri 64108, United States

2. Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, One Hospital Drive, Columbia, Missouri 65212, United States

Funder

National Institute on Alcohol Abuse and Alcoholism

National Institutes of Health

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00539

Reference50 articles.

1. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma

2. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

3. REGN-EB3: First Approval

4. Therapeutic antibodies: successes, limitations and hopes for the future

5. Strategies and challenges for the next generation of therapeutic antibodies

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities;Frontiers in Medicine;2024-06-07

2. Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors;ACS Medicinal Chemistry Letters;2024-05-28

3. Peptide-drug conjugates: A new paradigm for targeted cancer therapy;European Journal of Medicinal Chemistry;2024-02

4. Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction;Bioorganic & Medicinal Chemistry Letters;2024-02

5. Light-activated azobenzene peptide inhibitor of the PD-1/PD-L1 interaction;Chemical Communications;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3